342O Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial

B Neyns,J.K Schwarze,C Bertels,W Geens,J Tijtgat,G Awada,F Vaeyens,L Cras,A-M Vanbinst,H Everaert,A Michotte,M Bruneau,R Forsyth,S Tuyaerts,J Duerinck

doi:10.1016/j.annonc.2021.08.006

342O Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial

B Neyns, J.K Schwarze + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.006

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 1	License type: publisher-specific-oa

#Subsequent Cohorts #Recurrent Glioblastoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Intracerebral (iCE) administration (admin) of ipilimumab (IPI) and nivolumab (NIVO) plus IV admin of NIVO following resection of rGB was well tolerated and resulted in encouraging overall survival (OS)(Schwarze et al, JITC 2021). In 4 subsequent cohorts (A to D), the safety of intratumoral (iTU) admin of NIVO and IPI, followed by repeated intracavitary (iCA), or intrathecal (iTH) admin of NIVO +/- increasing doses of IPI was investigated.

Full Text